OAM
LOGC

Oxford Asset Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Oxford Asset Management’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-18,923
Closed -$136K – 1512
2019
Q4 		$136K Buy
+18,923
New +$171K ﹤0.01% 1597

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oxford Asset Management's LOGC Position: Q1 2020 in Review

Oxford Asset Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2020, closing a stake of 18,923 shares — an estimated $136K sold.

Oxford Asset Management first reported a position in LOGC in Q4 2019 and held it in 1 quarter. The position peaked at $136K in Q4 2019. 43 funds tracked by Wall St. Rank hold LOGC as of Q1 2020.

  • Oxford Asset Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 18,923 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $136K.
  • Oxford Asset Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Oxford Asset Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $136K in Q4 2019.
  • 43 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.